Jim Simons Nymox Pharmaceutical Corp Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.19 - $0.49 $1,630 - $4,204	-8,581 Reduced 12.37%	60,800 $12,000
Q1 2023 May 12, 2023	SELL	$0.33 - $0.5 $4,428 - $6,709	-13,419 Reduced 16.21%	69,381 $24,000
Q4 2022 Feb 13, 2023	BUY	$0.28 - $0.74 $23,184 - $61,272	82,800 New	82,800 $27,000
Q2 2022 Aug 12, 2022	BUY	$0.38 - $1.41 $7,501 - $27,836	19,742 New	19,742 $9,000
Q1 2021 May 13, 2021	SELL	$2.22 - $3.39 $149,992 - $229,041	-67,564 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$1.84 - $2.83 $58,261 - $89,609	31,664 Added 88.2%	67,564 $168,000
Q3 2020 Nov 13, 2020	SELL	$2.3 - $3.66 $53,992 - $85,918	-23,475 Reduced 39.54%	35,900 $88,000
Q2 2020 Aug 13, 2020	SELL	$2.1 - $4.6 $95,182 - $208,494	-45,325 Reduced 43.29%	59,375 $211,000
Q1 2020 May 14, 2020	BUY	$1.69 - $3.88 $116,642 - $267,793	69,019 Added 193.43%	104,700 $245,000
Q4 2019 Feb 13, 2020	BUY	$1.73 - $2.42 $28,183 - $39,424	16,291 Added 84.02%	35,681 $78,000
Q3 2019 Nov 13, 2019	BUY	$1.41 - $2.12 $6,330 - $9,518	4,490 Added 30.13%	19,390 $35,000
Q2 2019 Aug 12, 2019	BUY	$1.33 - $2.12 $19,817 - $31,588	14,900 New	14,900 $22,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.